APA (7th ed.) Citation

Danto, S. I., Shojaee, N., Singh, R. S. P., Li, C., Gilbert, S. A., Manukyan, Z., & Kilty, I. (2019). Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. BMC.

Chicago Style (17th ed.) Citation

Danto, Spencer I., Negin Shojaee, Ravi Shankar P. Singh, Cheryl Li, Steven A. Gilbert, Zorayr Manukyan, and Iain Kilty. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Selective Interleukin-1 Receptor-associated Kinase 4 (IRAK4) Inhibitor, in Single and Multiple Ascending Dose Randomized Phase 1 Studies in Healthy Subjects. BMC, 2019.

MLA (9th ed.) Citation

Danto, Spencer I., et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Selective Interleukin-1 Receptor-associated Kinase 4 (IRAK4) Inhibitor, in Single and Multiple Ascending Dose Randomized Phase 1 Studies in Healthy Subjects. BMC, 2019.